Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 18Prostatic Neoplasms, Castration-Resistant 3Neoplasm Metastasis 3Non-metastatic Castration-resistant Prostate Cancer 2Metastatic Castration Resistant Prostate Cancer 2Sleep Initiation and Maintenance Disorders 1Non-metastatic Prostate Cancer 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Fatigue 1Epilepsy 1Depression 1Castration-resistant Prostate Cancer 1Brain Diseases 1Advanced Prostate Carcinoma 1

Interventions

radium Ra 223 dichloride 1enzalutamide 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Castration-resistant Prostate Cancer × enzalutamide × Clear all
NCT02669771 2024-11-21

Long-Term Specified Drug Use-Results Survey for Xtandi Capsule

Astellas Pharma Inc

Completed
1,018 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡